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Paramagnetic gadolinium ions (GdIII), complexed within DOTA-based chelates, have become useful tools to increase the
magnetic resonance imaging (MRI) contrast in tissues of interest. Recently, “on/o” probes serving as 19F·MRI biosensors for
target enzymes have emerged that utilize the increase in transverse (T∗2 or T2) relaxation times upon cleavage of the paramagnetic
GdIII centre. Molecular 19F·MRI has the advantage of high specicity due to the lack of background signal but suers from low
signal intensity that leads to low spatial resolution and long recording times. In this work, an “on/o” probe concept is introduced
that utilizes responsive deactivation of paramagnetic relaxation enhancement (PRE) to generate 19F longitudinal (T1) relaxation
contrast for accelerated molecular MRI. e probe concept is applied to matrix metalloproteinases (MMPs), a class of enzymes
linked with many inammatory diseases and cancer that modify bioactive extracellular substrates. e presence of these bio-
markers in extracellular space makes MMPs an accessible target for responsive PRE deactivation probes. Responsive PRE
deactivation in a 19F biosensor probe, selective forMMP-2 andMMP-9, is shown to enable molecularMRI contrast at signicantly
reduced experimental times compared to previous methods. PRE deactivation was caused byMMP through cleavage of a protease
substrate that served as a linker between the uorine-containing moiety and a paramagnetic GdIII-bound DOTA complex.
Ultrashort echo time (UTE) MRI and, alternatively, short echo times in standard gradient echo (GE) MRI were employed to cope
with the fast 19F transverse relaxation of the PRE active probe in its “on-state.” Upon responsive PRE deactivation, the 19F·MRI
signal from the “o-state” probe diminished, thereby indicating the presence of the target enzyme through the associated negative
MRI contrast. Null point 1H·MRI, obtainable within a short time course, was employed to identify false-positive 19F·MRI re-
sponses caused by dilution of the contrast agent.
1. Introduction
e measurement of enzyme activity in vivo is a major
challenge for the development of enzyme-specic chemical
probes and will facilitate a deeper understanding of the role
of enzymes in biological processes and facilitate drug dis-
covery, synthetic biology, and metabolic engineering re-
search [1]. Matrix metalloproteinases (MMPs), a subclass of
proteases, are zinc(II)-dependent enzymes that typically
possess two ZnII ions, one for structural purposes and the
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other critical for catalysis. In humans, there are 24 diﬀerent
genes which code for 23 diﬀerent MMPs, with the ﬁrst and
last gene coding for the sameMMP [2]. Expressed in a latent
form prior to activation extracellularly, MMPs are an at-
tractive drug target, due to their selective activation location
outside the cell. MMPs remodel the extracellular matrix
(ECM) and also play key roles in a range of physiological
processes, including wound healing [3], organogenesis, and
modulation of inﬂammatory processes. MMPs are also in-
volved in pathological processes such as chronic obstructive
pulmonary disease (COPD) [4] and can be used as bio-
markers for determining stages of cancer, where the levels of
MMPs are correlated to metastatic potential [5].
Chemical probes to detectMMPs have been developed in
the ﬁeld of ﬂuorescent microscopy. Fo¨rster resonance energy
transfer- (FRET-) based MMP probes have been available
since the early 1990s [6], but in vivo imaging applications are
hampered by the limited tissue penetration of the short
wavelength light, inherently used for excitation and emission
in ﬂuorescent techniques. As a result, ex vivo studies have
been performed, for example, using probes to measure se-
rum MMP levels [7]. An alternative and noninvasive im-
aging modality is magnetic resonance imaging (MRI).
Chemical probes or responsive contrast agents have been
previously developed for use in 1H·MRI, providing in-
formation on a range of catalytic [8] and noncatalytic
processes such as monitoring pH [9], redox dysregulation
[10], and levels of metal ions such as zinc [11], calcium [12],
and copper [13]. However, to date, there have only been a
small number of examples of MMP MRI probes [14]. No-
table examples include iron oxide nanoparticles which have
been used to show changes in T2 relaxation times upon
conjugation with MMPs [15] and contrast agents which use
the concept of a solubility switch in which the T1 value is
altered due to the precipitation resulting from MMP ligand
cleavage [16].
A key hurdle in the successful application of 1H·MMP
probes is the confounding background signal from en-
dogenous water in the body, which makes contrast de-
termination diﬃcult. To overcome this problem, eﬀorts have
focussed on 19F, for which there is little detectable 19F
background signal in the body (except for bones, teeth and
calciﬁed tissue), leading to excellent speciﬁcity [17]. is is
an important requirement for a molecular probe and a key
advantage over 1H·MRI [18]. An exciting approach to
harness the eﬀect of paramagnetic GdIII upon 19F relaxation
was proposed by Mizukami et al. to study the enzyme ac-
tivity using a peptide of four amino acid residues that acts as
a substrate for caspase-3. A triﬂuoro aryl ether at the carboxy
terminus of the caspase-3 peptide substrate was linked with a
GdIII-DOTA chelate at its amine terminus [19]. In the initial
uncleaved form, the ﬂuorine signal is weak due to severe line
broadening by fast transverse relaxation (i.e., short T2 times).
However, in the presence of the speciﬁc enzyme, the linker
was cleaved and the distance between the GdIII DOTA and
ﬂuorine increased, causing a reduction of the paramagnetic
inﬂuence on ﬂuorine. e decreased transverse relaxation led
to an increase of the 19F signal due to line narrowing.e line-
narrowing response of the probe molecule—or biosensor
molecule—produces detectable MRI signal in regions where
the biosensor is co-located with the enzyme target. Using and
validating this concept, further 19F biosensor molecules were
designed to probe for β-galactosidase and β-lactamase ac-
tivities [20–22]. Previous developments also include a dual
ﬂuorescence 19F probe [23] and a dual 1H-19F·MRI probe
which in its precleaved form contained a labile carbamate
with a triﬂuoromethyl group in close proximity to a chelated
GdIII ion [24]. e 1H-19F probe was then activated by
β-galactosidase, which cleaved the carbamate resulting in the
release of the 19F source, in turn increasing the 19F·MRI signal
intensity. For MMP-2 detection, equivalent to the present
work, an “oﬀ/on” probe with nine equivalent 19F atoms as
signal source has been reported by Yue et al., which utilizes
this eﬀect of cleavage to alter the 19F transverse relaxation
properties [25, 26].
Although signiﬁcant progress has been made with
nonspeciﬁc 19F·MRI tracers for cell labelling, including
clinical applications [27, 28], the use of speciﬁcally targeted
19F·MRI probes for molecular imaging, in particular for in
vivo studies, is frustrated by inadequate 19F·MRI signal
intensity [29]. e MMP biosensor concept described above
utilizes reduced transverse (T2 or T∗2 ) relaxation; however,
the longitudinal relaxation is also reduced, and long T1 times
diminish the amount of signal averaging that is feasible
within the time span of typical in vivo MRI experiments.
In this work, we have explored a modiﬁed MMP 19F
biosensor detection protocol where the observation concept
is turned around by detecting the intact biosensor instead of
the cleaved molecule. e short 19F·T1 relaxation time of the
intact biosensor molecule is utilized for paramagnetic re-
laxation enhancement (PRE) [30–32] to improve the
19F·MRI signal to noise ratio (S/N) through rapid signal
averaging. MRI protocols are adjusted to handle the fast
transverse relaxation of PRE-activated biosensors. Re-
sponsive cleavage of the biosensor by the target protein
causes PRE to be “switched oﬀ” and the MRI signal to
disappear. e resulting negative MRI contrast is demon-
strated to serve as an indicator for the presence of MMP
biomarker molecules.
2. Materials and Methods
2.1. Synthesis of the Biosensor. To advance the concept of
responsive PRE deactivation, two diﬀerent “on/oﬀ” 19F·MRI
probes sensitive to MMP cleavage have been synthesized
using a short customisable synthetic route. e probes can
be split into three segments: (1) the ﬂuorine-containing
moiety, which delivers the signal; (2) the paramagnetic
moiety for PRE, which consists of a GdIII-bound DOTA-
complex; (3) the protease substrate which links together the
other two constituents and can be tailored to serve as
substrate to speciﬁc target for MMPs (see Figure 1 and also
Supporting Materials S1 for selected sequences). e main
focus of the current work is on the concept of molecular
contrast through responsive PRE deactivation using mo-
lecular probes that are mechanistically similar to theMMP-2
selective probe previously utilized by Yue et al. for T∗2
contrast [25]. Some changes in the probe structure and its
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synthesis have been made compared to [25]. In the previous
work, a PEG linker was incorporated for solubility of the
ﬂuorine-containing moiety and was attached to the MMP
substrate peptide via Michael addition of maleimide to the
thiol of the cysteine-containing substrate peptide. In the
current work, this type of linker, known to be labile due to
thiol exchange in vivo [33], was avoided, and the ﬂuorine
moiety was directly incorporated as amino acid side chain in
the peptide sequence; furthermore, GdIII-bound DOTA-
complex was linked to the peptide sequence using a stable
1,4-triazole formed using “click” chemistry. e molecule in
this work is soluble in 9 :1 (v/v) water/acetonitrile up to at
least 1.2mM concentration without a PEG linker, and the
solvent was acceptable for the proof of concept work and
tolerated by the enzyme. Furthermore, Yue et al. used
peptide-coupling chemistry to attach an octadentate GdIII-
DOTA chelator as the ﬁnal unit to their peptide. is
synthesis required 30 synthetic steps, two of which required
puriﬁcation by high-performance liquid chromatography
(HPLC). e probes in the current work required 27 syn-
thetic steps, with puriﬁcation via HPLC reserved for only the
ﬁnal step adding some eﬃciency. e synthesis is described
in detail in Supplementary Materials S1–S3.
2.2. MMP Preparation. Recombinant human carrier-free
MMP-1, MMP-2, MMP-9, and MMP-12 (R&D Systems,
Minneapolis, Minnesota) were diluted upon receipt to 75 µg/
ml in 50mMTris, 10mM·CaCl2, 150mM·NaCl, 0.05% (w/v)
Brij 35, and pH 7.5. MMPs were activated by incubation with
4-aminophenylmercuric acetate (APMA) at 100mM in
dimethyl sulfoxide (DMSO) (Sigma Aldrich, UK) was added
to a ﬁnal concentration of 1mM. Activation incubation
times at 310K were 1 hour for MMP1-1 and MMP-2 and 24
hours for MMP-9 and MMP-12. Following incubation,
enzymes were aliquoted and frozen at 193K until required.
A 5 μl aliquot was thawed and added to 600 µl of the bio-
sensor solution, immediately prior to the NMR experiments.
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Figure 1: Sketch of MMP responsive line narrowing and PRE deactivation. (I) GdIII PRE-activated 19F probe for sequence-speciﬁc MMP-9/
12, (II) GdIII PRE-activated 19F broad-range probe. Before cleavage, the GdIII is in close proximity to the 19F causing short T2 times that can
be observed as 19F·NMR line broadening. However, a strong paramagnetic relaxation enhancement (PRE) eﬀect is also present that enables
rapid signal averaging due to short T1 times. After cleavage (III), the distance r between the GdIII and the 19F moieties substantially increases,
leading to line narrowing but also to the deactivation of 19F·PRE due to the 1/r6 dependence of paramagnetic relaxation.
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2.3. Enzyme Activity Time Course Observed through 19F·NMR
Line Shape at 14.1 Tesla. 19F·NMR/MRI·MMP probe
(0.1mM in 9 :1 (v/v) H2O/D2O) was incubated with MMP-9
(5 µL, at 10 µg/mL, ﬁnal concentration 83 ng/mL) in a total
volume 600 µL adjusted to pH 7.5. e time point t� 0 for
each time course was right after MMP addition; sub-
sequently, the sample was reintroduced into the NMR
magnet and kept at the temperature speciﬁed. e bio-
sensor molecule (Figure 1) results to a single peak at –64
ppm (relative to CFCl3 at 0 ppm). e 19F·NMR lineshape
measurements (Figure 2) were obtained in a 5mm sample
diameter high-resolution probe head with 19F inner coil for
acquisition (1H outer coil for decoupling—not used) tuned
to the 19F frequency of 564.6MHz using a Bruker Avance
III 600MHz (14.1 Tesla) spectrometer. e ﬂuorine line-
width (FWHM) was used as a measure of the transverse
relaxation, T∗2 [34]. Measurements were taken at a tem-
perature of either 298 K or 310 K as indicated in the ﬁgure
and main text. e time dependence of the signal intensity
was analyzed using Lambert functions for a Michaelis-
Menten ﬁt to obtain the enzyme eﬃciency parameter listed
in Table 1.
2.4. 19F·NMR T1 Relaxation Measurements at 14.1 Tesla.
Longitudinal relaxation rates (T1) for the ﬂuorinated mo-
lecular probes were determined in an inversion recovery
experiment at 298K with 14 to 28 inversion recovery times
and a repetition time (TR) of up to 8 seconds to insure full
magnetization recovery (Table 2). NMR spectrometer and
probe head were identical to those described above the
linewidth measurements.
2.5. 19F·NMRT1 andT2 RelaxationMeasurements at 9.4 Tesla.
All bulk relaxation measurements (i.e., without spatial res-
olution) at 9.4Tesla were obtained for samples contained
within a single 5mm NMR sample tube located in the centre
(i.e., axial location) of a 30mm (sample diameter) 19F
microimaging probe head (Bruker) tuned to 376.5MHz using
a Bruker Avance III 400MHz (9.4Tesla) spectrometer and
microimaging system. e temperature for all 9.4 Tesla
measurements was 293K. e T1 and T2 relaxation times of
intact (PRE activated) 19F biosensor dissolved at concentra-
tions ranging from 0.3–1.2mM in 9 :1 (v/v) water/acetonitrile
(ACN) were obtained using standard inversion recovery and
spin echo experiments, respectively. A 82 μs rectangular 90°
pulse was used for excitation, and 164 μs rectangular 180°
pulses was used for inversion and refocusing. e integrated
signal intensity and signal heights were obtained from 12–14
inversion recovery and spin echo measurements with a signal
averaging of 1024 scans. Likewise, inversion recovery and spin
echo measurements were also performed with the cleaved
biosensor after completed reaction with the MMP. Recovery
times of at least 5 T1 times were used for all measurements (up
to 2.5 s) at the range of recovery and spin echo times that
allowed for at least 90 % recovery or 90% decay, respectively.
e resulting curves were analysed using Igor Pro 7, and the
average from signal intensity curves and integrated intensities
are reported in Figure 3.
2.6. 19F·MRI Protocols at 9.4 Tesla to Monitor MMP Activity.
All MRI were recorded using a Bruker Avance III 400MHz
(9.4 Tesla) microimaging system with a 19F frequency of
376.4MHz at 293K. e sample for MRI were contained
within three or ﬁve (see Figures 4 and 5, respectively) 5mm
NMR sample tubes located in a custom-made 30mm sample
holder placed into a 30mm 19F Bruker microimaging probe
head tuned to 376.5MHz. e samples in each tube are
described in the ﬁgure captions.
2D transverse ultrashort echo time (UTE) 19F·MR im-
ages (30mm slice thickness) of a sample containing three
5mm NMR tubes (Figure 4) were obtained from 202 pro-
jections and used a polar undersampling factor of 1. Images
were reconstructed to a 64× 64 data point resolution. e
ﬁeld of view was FOV� 25mm× 25mm. A 300 μs Gaussian
90° excitation pulse was used, TE was 191 μs, repetition time
was 5ms, and 360 averages were taken that lead to a total
scanning time of 6min.
2D transverse spin echo 19F·MRI (30mm slice thickness)
of sample containing three 5mmNMR tubes (Figure 4) used
a 1ms Gaussian 90° excitation pulse, 10.29ms echo time,
200ms repetition time, and 360 averages.
FOV� 30mm× 30mm at 32× 32 point resolution (raw
data) recorded at a total acquisition time of 77min. For
processing, a sinebell apodization and zero ﬁlling to 64× 64
data points were applied.
2D transverse gradient echo 19F·MRI (50mm slice
thickness) of sample containing ﬁve 5mm NMR tubes
(Figure 5) used 873 μs echo time, 20ms repetition time, and
1536 averages. FOV� 30mm× 30mm at 32× 32 point
resolution (raw data) recorded at a total acquisition time of
16min. For processing, a sinebell apodization and zero
ﬁlling to 64× 64 data points were applied.
2.7. 1H·MRI Protocols at 9.4 Tesla. e 2D gradient echo
(GE) 1H·MRI (2mm slice thickness) of sample containing
ﬁve 5mm NMR tubes (Figure 5) used a standard GE pro-
tocol with 1.4ms rectangular 90° excitation pulse, 2.5ms
echo time, 2000ms repetition time, and no signal averaging.
FOV� 30mm× 30mm at 64× 64 data point (raw) resolu-
tion recorded at a total acquisition time of 2½ min at 293K.
For processing, a sinebell apodization and zero ﬁlling to
128×128 points were applied.
e 2D null point 1H·MRI (2mm slice thickness) of the
sample in Figure 5, containing ﬁve 5mm NMR tubes, used
an inversion recovery protocol with 4.84ms rectangular 180°
inversion pulse, 220ms inversion recovery time, 2.5ms echo
time, 2000ms repetition time, and no signal averaging.
FOV� 30mm× 30mm at 64× 64 data point resolution
recorded at a total acquisition time of 2½ min at 293K. For
processing, a sinebell apodization was applied with zero
ﬁlling to 128×128 points.
3. Results and Discussion
3.1. Following Enzymatic Activity through NMR Linewidth.
Intramolecular paramagnetic relaxation, the dominating re-
laxation mechanism for the 19F nuclear spins in the intact
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biosensor molecule, will be replaced by intermolecular
paramagnetic relaxation after biosensor cleavage through
MMP (Figure 1). e spatial separation r between the 19F-
containing unit and the paramagnetic Gd DOTA complex
will substantially increase by the cleavage, causing a dramatic
reduction in the 1/r6-dependent paramagnetic relaxation for
19F. is means that 19F·PRE is eﬀectively “turned oﬀ” by the
biosensor response to MMP.
e 19F·NMR linewidth narrowing, associated with
cleavage, as previously utilized by Yue et al. [25, 26], was
used in this work for the initial testing of the biosensor and
to explore both temperature and also isotope eﬀects on the
sensor kinetics. e isotope eﬀect of deuterium on the
cleavage reaction is of interest as D2O is typically used as a
lock solvent in NMR spectroscopy. e MMP-2/-9 selective
probe was incubated with APMA- (4-aminophenylmercuric
acetate-) activated MMP-9 under three diﬀerent sets of
Table 1: kcat/KM for both probes under all conditions.
Probe Solvent Temp (K) kcat/KM (M−1·s−1)
MMP-2/-9 H2O 310 726
MMP-2/-9 H2O 298 267
MMP-2/-9 D2O 298 56.5
Generic H2O 310 75.9
Generic H2O 298 207
Generic D2O 298 108
H2O as a solvent denotes v/v 9 :1 H2O/D2O.
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Figure 2: 19F·NMR spectroscopy ofMMP-mediated biosensor cleavage at 14.1Tesla. (a) 19F·NMR lineshape of 0.1mM-speciﬁcMMP-2/-9 probe as a
function of time at 298K. After MMP-9 was added at t� 0, the NMR signal of the probe showed an increase in the amplitude and sharpening of the
peak. (b)Time course ofNMRsignal intensity (amplitude) of the speciﬁcMMP-2/-9 probe (0.1mM) as a function of time afterMMP incubationunder
diﬀerent conditions: at 298K in pure D2O, at 298K in v/v 9 :1 H2O/D2O, and at 310K in v/v 9 :1 H2O/D2O.e fastest reaction rate was observed at
physiological temperatures (310K). (c) Time course of NMR signal intensity (amplitude) of the broad-range probewithMMP-9 added at t� 0. For the
broad-range probe, the reaction rate was fastest at room temperature (298K), in contrast to the optimal conditions for the speciﬁc MMP-2/-9 probe.
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conditions (i.e., D2O at 298K, H2O at 298K, and H2O at
310K). Before the addition of MMP-9 the 19F·NMR peaks
observed were broad, with a full width at half maximum
(FWHM) of ∼60Hz (310K). After addition of MMP-9, a time
series of 19F·NMR experiments was performed to monitor the
progress of the enzymatic reaction. e observed line nar-
rowing with reaction time in Figure 2(a) indicates the pro-
gressive cleavage of the biosensor with associated reduction in
the transverse paramagnetic relaxation.
e amplitude of the single 19F peak at −64 ppm (relative
to CFCl3 at 0 ppm) was measured and used to plot peak
amplitude versus time. Postcleavage, the FWHM was re-
duced to 19Hz (310K), caused by the increase in distance
between the GdIII ion and the 19F signal source. ese ex-
periments were repeated with the broad-range probe under
identical conditions, and a FWHM of ∼53Hz precleavage,
and 13Hz postcleavage (310K) was observed (not shown).
e time course of the NMR signal under the three
diﬀerent sets of conditions (varying solvent and tempera-
ture) is shown for the MMP-2/-9 probe in Figure 2(b) and
for the broad-range probe in Figure 2(c). In order to
compare the relative conditions and probes, we calculated
the speciﬁcity constant (enzyme eﬃciency), kcat/KM, for both
probes under each set of condition (Table 1). Here, kcat is the
turnover number (per second) and KM the apparent
(Michaelis) binding constant. e enzyme eﬃciency was
calculated by mapping the time dependence of amplitude of
the signal peak and then applying a Michaelis-Menten based
ﬁt using Lambert functions and least squares ﬁtting [35].
At physiological temperatures, the MMP-2/-9 probe was
almost completely cleaved within an hour. e enzyme was
ﬁvefold more eﬃcient (seen in the change in kcat/KM) if the
solvent contained 10% v/v D2O rather than 100% D2O (at
298K). A similar trend was observed with the broad-range
probe, where the enzyme was twice as eﬃcient in 10% v/v
D2O rather than pure D2O. Intriguingly, we observed that, in
contrast to the speciﬁc MMP-2/-9 probe, the turnover of the
broad-range probe was slower at physiological conditions
than at lower temperatures, with kcat/KM at 310K for the
broad-range probe reaching only a third its value at 298K.
One explanation may be that at higher temperature, the
broad-range probe may occupy a diﬀerent conformation,
making it less readily accepted by MMP-9 and thereby
increasing KM and/or decreasing kcat for the generic probe.
When compared to the FRET substrate described by
Knight et al. [6], the NMR probe is substantially more slowly
turned over, an observation which can potentially be at-
tributed to the relatively bulky GdIII-DOTA chelate reducing
the MMP-9 binding aﬃnity for the NMR probe.
3.2. Selectivity of theProbe. To test the speciﬁcity of the probe,
the MMP-2/-9 probe was incubated with MMP-1 and MMP-
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Figure 3: Dependence of 19F relaxation rates ρ1 � T−11 and ρ2 � T−12 on the biosensor concentration [Rx]. Measurements taken at 9.4 Tesla
and 293K using the MMP-2/-9 speciﬁc biosensor diluted in 9 :1 v/v H2O/acetonitrile mixture. (a) 19F relaxivity ρ1/[Rx] measurement of the
intact biosensor revealed no detectable concentration dependence of 19F longitudinal relaxation with an approximate average value of
ρ1 � 93 s−1·ms (red dashed line). (b) e transverse relaxation rate of the intact biosensor also exhibited little dependence on [Rx] with an
average of ρ2 � 298 s−1·ms (red dashed line). (c, d) After MMP-2 responsive biosensor cleavage, a strongly reduced and concentration [Rx]-
dependent longitudinal and transverse relaxation rates (ρ1 and ρ2, (c) and (d), respectively) was observed. e solid blue lines in (c) and (d)
show data ﬁtting for relaxivity ρ/[Rx] deﬁned by a concentration [Rx]-dependent part ρ[Rx] and a concentration independent oﬀset ρ0
(Table 3 for determined values).
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12, leading to no observable cleavage, as conﬁrmed by mass
spectrometry to detect the cleaved products (data not shown).
e broad-range probe however responded as expected to all
MMPs tested (MMP-1, MMP-2, MMP-9, and MMP-12).
3.3. Transverse and Longitudinal 19F Relaxation of the 0.1mM
Biosensor in Aqueous Solution. Longitudinal 19F relaxation
times T1 for the ﬂuorinated probes and transverse relaxation
times T∗2 , determined by inversion recovery experiments and
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5mm
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t = 2h
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t = 10ht
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Figure 4: Transverse 19F·MRI at 9.4Tesla and 293K of three separate 5 mmNMR tubes (located within a 30mmmicroimaging probe head), each
containing 600μL of 1.2mM solution of the respective 19F samples in 9 :1 v/v H2O/acetonitrile solution, were used to demonstrate the eﬀect of
negative T1 contrast for molecular imaging. (a) Sketch of the sample (transverse view): (i) 1.2mM biosensor without MMP. (ii) 1.2mM biosensor
withMMP-2 added at t� 0 s. (iii) 19F control containing 1.2mMof tetraﬂuoroacetate (TFA) and 1.2mMofGd-DOTA. Samples were kept at 293K
throughout the reaction. (b) T1 weighted 19F·UTE·MRI at various times withMMP-2 added to sample (ii) at t� 0 demonstrating negative contrast
with progressing time. (c) T2 19F weighted spin echo (SE) MRI demonstrating the eﬀect of positive contrast. Recording time t (rounded to the
nearest full hour) indicates the beginning of the UTEMRI acquisition (6min recording time per image) that is followed after completion by the SE
MRI (75min recording per image).
Contrast Media & Molecular Imaging 7
from the ﬂuorine linewidth (FWHM) [34], respectively, are
listed in Table 2. Upon cleavage, the two diﬀerent MMP
probes display drastic changes in their T1 and T∗2 times. e
MMP-2/-9 probe shows an increase in T1 by a factor of over
60, whereas the generic probe increases the T1 time by a
factor of 75. Cleavage also leads to an increase in T∗2 by a
factor of about 7 and 10 for the MMP-2/-9 probe and the
generic probe, respectively, and by a factor of 20 in the
i
ii
iii
iv
i
ii
iii
iv
iii
ii
iv
v
iii
iv
v
iii
i
ii
iii
iv
v
5mm
5mm 5mm
Sample ii: MMP added
Sample iii: diluted from 0.6mM to 0.4 mM
(a)
(b) (c)
(d) (e)
(f) (g)
Figure 5: T1 weighted 19F and 1H·MRI of samples containing PRE active and MMP-2 cleaved (PRE deactivated) 19F biosensors at 9.4Tesla
(transverse view). Samples in ﬁve separate NMR tubes located in a 30mm microimaging probe head at 293K (i) 0.6mM biosensor (no MMP-2
added), (ii) 0.6mM biosensor with MMP-2 added after acquisition of images (b) and (c), (iii) 0.6mM biosensor, diluted to 0.4mM concentration
after images (b) and (c) acquisition, (iv) 0.4mM cleaved biosensor (cleaved throughout all images), and (v) PBS solution without any Gd(III) or 19F
present. (a) 1H gradient echo (GE)MRI (of H2O) showing all samples. (b)T1 weighted 19F·GE·MRI showing three samples with 0.6mMPRE active
(not cleaved) biosensor probe. (c) 1H null point MRI (of H2O) with inversion recovery time (TI) set to 220ms leading to vanishing signal in the
samples with PRE active biosensor. (d) T1 weighted 19F·GE·MRI after MMP-2 catalysed cleavage of biosensor in sample (ii) and dilution of sample
(iii) to 0.4mM. (e) 1H null pointMRI (of H2O) with TI� 220ms revealing the concentration change of sample (iii) (false positive). (f) Diﬀerence of
T1 weighted 19F·GE·MRI (d subtracted from b). (g) Absolute value of the diﬀerence of 1H·IR·MRI (e subtracted from c).
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previous work at 7 Tesla [25, 26]. e linewidth eﬀect,
utilized in previous literature, may therefore lead to a less
pronounced change in the MRI contrast than that caused by
the reduction of the longitudinal relaxation. Note that
however the relaxation diﬀerences between the intact and
the cleaved sensor are strongly dependent on the sensor
concentration as explored in detail further below.
3.4. 19F Relaxation Behaviour of the Biosensor at 9.4 Tesla.
e data in Figure 2 and Table 2 were obtained with a 5mm
high-resolution probe at 14.1 Tesla (564.6MHz 19F reso-
nance frequency) and a biosensor concentration of 0.1mM.
e biosensor concentration was increased to ≥0.4mM to
provide suﬃcient signal intensity for molecular 19F·MRI at
9.4 Tesla (376.4MHz 19F resonance frequency) using a
30mm 19F microimaging coil for excitation and detection.
To dissolve the biosensor up to a 1.2mM concentration, a 9 :
1 (v/v) H2O/acetonitrile mixture was used as a solvent at
293K. e eﬀect of acetonitrile on the kinetics of biosensor
cleavage by the enzyme MMP-2 was studied in assays (not
shown here). Although the presence of 10% ACN reduced
the reaction kinetics, it still allowed for cleavage of the sensor
with MMP-2. All relaxation measurements at 9.4 T were
performed at a temperature of 293K.
e biosensor concentration [Rx] dependence of the 19F
relaxation rate, i.e., the biosensor 19F relaxivity, is crucial for
the concept development of molecular MRI contrast ex-
plored here. As shown in Figure 3 and listed in Table 3, the
intact MMP-2/-9 biosensor does not exhibit a concentration
dependence for the longitudinal relaxation with
T1 � 10.7± 1.0ms. e observed value is about 30% shorter
than the value listed in Table 2 with T1 � 15.1ms for the
intact biosensor at 0.1. mM concentration obtained in
aqueous solution (containing 10% D2O) at 14.1 Tesla
magnetic ﬁeld strength and 298K. Similarly, the transverse
relaxation of the intact biosensor in Figure 3 exhibited little
concentration dependence, and the average value was found
to be T2 � 3.46± 0.42ms (note that T2 relaxation times and
rates, as determined by spin echo measurements, are re-
ported here as they provide more precise data than T∗2
measurements that are aﬀected by sample susceptibility).
Upon catalytic cleavage with MMP, the relaxation rates are
dramatically reduced. At the same time, the relaxation rates
start to exhibit a strong dependence upon (cleaved)
biosensor concentration [Rx]. However, even at a relatively
high concentration of [Rx]� 1.0mM, the 19F longitudinal
relaxation rate is slowed down by a factor of 25 upon
cleavage, leading to a longitudinal relaxation time of
T1 � 267± 37ms. Similarly, transverse relaxation is slowed
20-fold upon cleavage, resulting to a transverse relaxation
time of T2 � 72.7± 2.5ms.
e transverse and longitudinal relaxivity (i.e., [Rx]
dependence of 19F relaxation) obtained from data in Figure 3
is listed in Table 3.e T1 relaxivity for the cleaved biosensor
interpolated for 9 :1 (v/v) H2O/ACN solutions to a con-
centration of [Rx]� 0.1mM (Figure 3 and Table 3) is
T1 � 796ms, a value that falls about 17% short of the value
T1 � 960ms listed in Table 2 for the aqueous solution (10%
D2O), indicating a qualitatively very similar relaxation be-
haviour of the cleaved biosensor within the two solvents.
3.5. Molecular Imaging Using Negative T1 Weighted MRI
Contrast through PRE Deactivation. e results of Figure 3
show that, upon cleavage, both transverse and longitudinal
relaxations slow down by more than an order of magnitude,
even if very high concentrations of up to 1.2mM biosensor
are being used. e eﬀect on transverse relaxation has been
exploited in the past to generate positive MRI contrast
through increasing 19F biosensor signal intensity that in-
dicates the presence of MMP. Figure 4 shows a repeat of this
concept with the MMP-2/-9-speciﬁc biosensor (Figure 4(c))
but also demonstrates (Figure 4(b)) that T1 contrast can be
exploited through ultrashort imaging time (UTE) 19F·MRI
[28, 36, 37]. e T1 weighted MRI produces a negative
contrast that is caused by the deactivation of the para-
magnetic relaxation eﬀect (PRE) on the 19F signal upon
cleavage through MMP. An important advantage of the T1
weighted contrast, as for PRE in general, is the fast data
acquisition that signiﬁcantly reduces the required experi-
mental time.
e UTE images in Figure 4 were employed to allow for
MRI of the intact biosensor despite the short T2 times and
fast repetition times (5ms recycle delay) enabled recording
within 6min each, whereas the spin echo MR images that
used T2 contrast took 75min each due to the long recycle
delay of 200ms to allow for suﬃcient, but still incomplete, T1
relaxation of the cleaved sensor. T1 weighted 19F·MRI
contrast of the intact biosensor with active PRE beneﬁts
from the UTE methodology that enables the recording of
Table 2: Relaxation times for MMP probes (0.1mM) with MMP-
2/-9 and generic sequence speciﬁcity at 14.1 Tand at 298K using v/
v 9 :1 H2O/D2O as a solvent.
Cleavage state T1 (ms) T∗2 (ms)a
MMP-2/-9-speciﬁc sequence Pre 15.1 <2.6bPost 961 18.2
Generic MMP sequence Pre 12.8 <2.3Post 960 23.8
ae T∗2 value was calculated using the relation, T∗2 � (πΔv)−1, where Δv is the
linewidth of the ﬂuorine peak at full width half maximum. be inability to
properly identify the exact linewidth of the precleaved state due to the broad
linewidth; hence, the maximum linewidth is used, yielding a minimum T∗2 value.
Table 3: Biosensor relaxivity for 19F at 293K and 9.4 Tesla obtained
from Figure 3 relaxation data ﬁtting using equations 1/
T1 � ρ1 � ρ1[Rx] ∗ [Rx] + ρ01 and 1/T2 � ρ2 � ρ2[Rx] ∗ [Rx] + ρ02.
Intact biosensor Cleaved biosensor
ρ1
ρ1 � 92.9± 7.3 s−1 ρ1[Rx] � 2.76± 0.40 s−1mM−1
T1 � 10.7± 1.0ms
(Figure 3(a))
ρ10 �+0.98± 0.33 s−1
(Figure 3(c))
ρ2
ρ2 � 289± 4 s−1 ρ2[Rx] � 9.85± 0.37 s−1·mM−1
T2 � 3.46± 0.42ms
(Figure 3(b))
ρ20 � 3.90± 0.30 s−1
(Figure 3(d))
Data are for biosensor with MMP-2/-9-speciﬁc sequence using MMP-2 as
the cleavage enzyme.
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signals with very short T2 times. However, as shown in
Table 3, the intact biosensor has a fairly large transverse to
longitudinal relaxation ratio of T2/T1 ≈ 0.3 with
T2 � 3.46ms and UTE MRI, although helpful, is not abso-
lutely required. UTE MRI is an excellent methodology for
systems with very short transverse relaxation times, but it is
experimentally demanding (i.e., requires trajectory cali-
bration), in particular if used for systems with inherently low
signal intensity. Figure 5 demonstrates that, for the par-
ticular molecule used in this study, 19F biosensor imaging is
also feasible through a simple gradient echo (GE) sequence.
e 19F·GE·MR images shown in Figures 5(b) and 5(d) were
each recorded within 16min using an echo time of
TE� 0.873 μs (the shortest possible with the hardware used),
signal averages NS� 1536, and a repetition time of
TR� 20ms. Figure 5(b) shows three sample tubes with 0.6
mM biosensor solution. e biosensor in all three sample
tubes was 0.6mM (i.e., half the concentration of the samples
used for UTE MRI in Figure 4).
e appearance of negative 19F contrast of the biosensor
obtained through the T1 weighted protocols described in this
work indicates the presence of MMP through responsive
PRE deactivation. However, transport phenomena within in
vivo organisms may cause negative contrast through bio-
sensor dilution and therefore would produce a false-positive
response. To distinguish the MMP catalysed biosensor re-
action from the false positive due to biosensor dilution, it is
instructive to utilize additional T1 sensitive 1H·MRI mea-
surements. Figure 5(b) shows the 19F·MRI of three sample
tubes, (i), (ii), and (iii) that contain the intact biosensor at
0.6mM concentration. In Figure 5(d), only sample tube (i)
contains the intact biosensor at this concentration while
MMP-2 was administered to sample (ii), and sample tube
(iii) was diluted to 0.4mM concentration of the intact
biosensor. e 19F·MR image in Figure 5(d) shows very
similar reduction in intensity for the two samples (ii) and
(iii). After >5 h incubation with MMP, the 19F longitudinal
relaxation time of sample (ii) displayed an increase from
T1 � 10.7ms for the intact sensor to approximately
T1 � 275± 15ms (i.e. using single exponential ﬁt), a value
that remained stable throughout the further experiments.
e observed 19F relaxation time value falls a little short of
T1 � 380ms, the expected value from Table 3 for the com-
pletely reacted sensor at 0.6mM concentration. e cause of
this deviation was not further investigated as it is of little
consequence for the proof of concept demonstrated here.
For better visualization, Figure 5(f) shows the result from
the subtraction of the MR image of Figure 5(d) from
Figure 5(b).
e T1 relaxation in 1H·MRI is strongly aﬀected by the
paramagnetic Gd(III) concentration, but the relaxation is
always intermolecular in nature. erefore, unlike 19F·T1
relaxation, the 1H·T1 relaxation is not aﬀected by the
cleavage of the gadolinium group from the 19F containing
moiety. e 1H longitudinal relaxation of the 0.6mM intact
sensor in (ii) was found to be T1 � 320ms both before and
after incubation with MMP. Figure 5(a) shows the 1H
gradient echo MRI of three tubes with 0.6mM biosensor
before MMP and dilution; tube (vi) contains 0.4mM of a
completely cleaved biosensor (recycled from a previous
experiment) that causes a weak signal in Figures 5(b) and
5(d); and sample tube (v) contains only PBS solution without
19F or gadolinium. Figure 5(c) depicts 1H null point MRI
using inversion recovery protocol with an inversion recovery
time TI� 220ms that causes all signals from tubes con-
taining 0.6mM biosensor solution to vanish due to zero
crossing.
Figure 5(e) shows the result from an identical 1H null
point MRI protocol but with the samples as in Figure 5(d)
(i.e., (ii) partially reacted through MMP and (iii) diluted to
0.4mM intact biosensor). As expected, there is no observable
change in 1H·T1 relaxation of the reacted biosensor in (ii),
but the diluted sample in (iii) leads to a strong inversion
recovery signal increase due to reduced 1H·T1 relaxation that
produces a clearly visible 1H·MRI response. e 1H·MRI
response, shown in Figure 5(e), identiﬁes the 19F·MRI re-
sponse for sample (iii) as false-positive. For better visuali-
zation, Figure 5(g) depicts the 1H null point MRI diﬀerence
between Figures 5(e) and 5(c).
3.6. Towards In Vivo MRI: Tasks for MMP Biosensor
Development. e results presented in Figures 4 and 5
demonstrate the eﬀectiveness of responsive PRE contrast
for molecular imaging but also indicate where future de-
velopment is required. False-positive signals due to bio-
sensor dilution can be eliminated by fast null point 1H·MRI
measurements of H2O that was completed within a total
recording time of 2½ min in Figure 5. Within an organism,
the biosensor localization may not be known quantitatively
and, additionally, dilution due to transport mechanisms will
occur over time. erefore, 1H·MRI·T1 maps may provide
detailed insights into biosensor concentration throughout
the organism. To generate “snapshots” of the concentration
distribution, the T1 maps need to be recorded quickly which
should not be a problem as abundant water molecules are
being detected and improved 1H·MRI protocols and/or
reduced resolution may accelerate the acquisition further.
Detailed GdIII concentration maps will then enable
19F·PRE·MRI data analysis to extract quantitatively the ex-
tent of the reaction. It is important to note that the pre-
viously explored transverse (T∗2 ) relaxation-based biosensor
detection concept can also beneﬁt from 1H·MRI·T1 maps. In
analogy to a false-positive response with a PRE-based bio-
sensor, a false-negative response may occur for T∗2 bio-
sensors because dilution will diminish the 19F·MRI signal,
and this can mask the presence of the target enzyme. As a
word of caution for NMR spectroscopic studies, the rate of
enzymatic hydrolysis of the probes was found to be sig-
niﬁcantly aﬀected by the percentage of D2O present in the
solution.
To advance the responsive PRE deactivation concept
towards in vivo applications, future biosensor synthesis will
need to address three key issues: (1)e biosensors will need
to be fully water soluble to enable the concentration required
for MRI. At the same time, the water soluble biosensor needs
to be stable within the in vivo environment. (2) A relatively
high concentration of the probe molecule was required in
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order to perform the MR imaging experiment in the current
and previous studies. e 19F signal intensity [29] requires
further improvement to be viable for in vivo applications.
Generally, various successful eﬀorts have been made to
improve the signal intensity by increasing the 19F spins per
molecule unit [38, 39], and these approaches need to be
explored to make responsive PRE deactivation more bio-
compatible by reducing the required concentration of bio-
sensor molecules. Furthermore, reducing the required
biosensor concentration will also enhance the molecular
MRI contrast due to an increased T1 relaxivity gap between
the PRE-activated and the PRE-deactivated probe molecule.
As shown in Figure 3, the relaxivity of the “oﬀ-state” exhibits
a strong concentration dependence while the “on-state”
relaxivity is largely unaﬀected by concentration changes. (3)
A paramagnetic group producing fast T1 but relatively slow
T2 relaxation (i.e., a high ratio close to the limit T2/T1� 1)
will further improve the presented concept. e para-
magnetic system used in this work, GdIII, generally produces
very unfavourable T2/T1 ratios that are also dependent on
the separation between the paramagnetic centre and the
ﬂuorine spins [40]. Distance cannot always be freely selected
in functionalized sensors but a variety of better options than
GdIII for the paramagnetic centre, such as FeII, TmIII, and
HoIII, have been explored to improve 19F·MR signal in-
tensities through increased the T2/T1 ratios [34, 39, 40].
Combining high T2/T1 ratios with an increased number of
19F spins, Kislukhin and coworkers have reported promising
results with paramagnetic ﬂuorinated nanoemulsions [28].
Lastly, the presented concept may also work for mo-
lecular imaging with hyperpolarized (hp) 129Xe, a contrast
agent that is becoming more readily available [41, 42]. A
recent study demonstrated a conceptual “on/oﬀ” probe with
a cryptophane cage that temporarily binds xenon atoms and
brings them into close proximity to the paramagnetic GdIII
centre. Deactivation of the paramagnetic relaxation of the
probe molecule caused an eight-fold reduction in the T1
relaxation of 129Xe in the solvent [43]. Note that hp 129Xe can
in principle be added long after the probe molecule has been
administered to an organism and after any deactivating
reaction has occurred in regions with up-regulated bio-
marker targets. Replacement of 19F with exogenous hp 129Xe
for MMP biosensor probe molecules may therefore be an
option to signiﬁcantly increase the signal from such enzy-
matic probes.
4. Conclusions
e usage of responsive PRE deactivation for T1 weighted
19F·MRI contrast, presented in this work, enables accelerated
observation of MMP enzyme activity by taking advantage of
the signiﬁcantly reduced imaging time compared to the
previously utilized T2 or T∗2 weighted MRI. UTE 19F·MRI
can be employed if problems associated with short 19F·T2
relaxation need to be overcome. In this work, UTE·19F·MRI
allowed for a more than 12-fold reduction in the total ac-
quisition time compared to a T2 weighted spin echo MRI
protocol. Alternatively, even a simple T1 weighted gradient
echo sequence enabled molecular MRI of MMP-2 within a
short acquisition time and with a reasonable signal to noise
ratio despite the unfavourable T2/T1 ratio of the GdIII system
used in this proof of concept study. Responsive PRE de-
activation for T1 weighted MRI leads to a negative contrast
where the intact biosensor is observed and the disappearance
of the MRI signal indicates cleavage due to enzyme activity.
False-positive identiﬁcation, where vanishing 19F·MRI sig-
nals are caused by biosensor dilution, can be identiﬁed
through additional T1 weighted 1H·MRI that is not aﬀected
by the biosensor cleavage. More progress is needed to ad-
vance targeted biosensors with responsive PRE deactivation
towards in vivo and clinical applications. is includes
improved molecular design of 19F biosensors but also the
advancement of hyperpolarized 129Xe biosensors with re-
sponsive deactivation of paramagnetic relaxation [43]. If
successful, this concept oﬀer signiﬁcant prospects for
monitoring disease progression and treatment impact with
much improved precision and therefore could play an
important role in personalized medicine.
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